The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in these filings, which are based on their September 30 holdings, data that is available nowhere else. Should you consider Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for your portfolio? We’ll look to this invaluable collective wisdom for the answer.
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) investors should be aware of an increase in hedge fund interest lately. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Javelin Mortgage Investment Corp (NYSE:JMI), MeetMe Inc (NASDAQ:MEET), and Hansen Medical, Inc. (NASDAQ:HNSN) to gather more data points.
To the average investor, there are dozens of tools shareholders have at their disposal to analyze their stock investments. Two of the most underrated tools are hedge fund and insider trading activity. We have shown that, historically, those who follow the best picks of the top investment managers can beat their index-focused peers by a significant amount (see the details here).
With all of this in mind, we’re going to take a look at the fresh action surrounding Actinium Pharmaceuticals Inc (NYSEMKT:ATNM).
What have hedge funds been doing with Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)?
Heading into Q4, a total of 5 of the hedge funds tracked by Insider Monkey were long this stock, an increase of 67% from the previous quarter. With the smart money’s capital changing hands, there exists a select group of key hedge fund managers who were upping their stakes significantly (or already accumulated large positions).
When looking at the institutional investors followed by Insider Monkey, Millennium Management, managed by Israel Englander, holds the biggest position in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM). Millennium Management has a $0.3 million position in the stock, comprising less than 0.1% of its 13F portfolio. The second most bullish fund manager is Nathan Fischel of DAFNA Capital Management, with a $0.2 million position; 0.2% of its 13F portfolio is allocated to the stock. Other peers with similar optimism include Hal Mintz’s Sabby Capital, Ken Griffin’s Citadel Investment Group, and Dmitry Balyasny’s Balyasny Asset Management.